ClinicalTrials.gg
RecruitingNCT07425522Updated Nov 9, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)

A Phase 1 interventional study of RO7823653 and Faricimab in Diabetic Macular Edema, sponsored by Genentech, Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 28 studies in Macular Edema by Hoffmann-La Roche — 1 open to participants now, 5 under way, 1 of them phase 3. Macular Edema · Hoffmann-La Roche.

Planned enrollment
22nd of 25
93 · median 377
Started
2026
the only one that year
Phase 1
3 of 28
1 open now
Registered
28th of 28
by date

Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1, and was the 28th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 28 studies in Macular Edema by Hoffmann-La Roche is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Macular Edema by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as monotherapy and co-administered with faricimab.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of diabetes mellitus (type 1 or type 2), as defined by the World Health Organization (WHO) and/or American Diabetes Association
  • (HbA1c) \<= 12%
  • For study eye: Macular thickening secondary to DME involving the center of the fovea with central subfield thickness (CST) >= 325 micrometers (µm) as measured by SD-OCT and BCVA of 65 to 35 letters

Exclusion criteria

Exclusion Criteria:

  • Currently untreated diabetes mellitus or previously untreated participants who initiated oral anti-diabetic medication or insulin within 90 days prior to Day 1
  • Pregnant or breastfeeding, or intending to become pregnant during the study or within the timeframe in which is required
  • Uncontrolled blood pressure
  • For Parts 1 and 2: Any history of ocular injection/implant therapy (e.g., anti-vascular endothelial growth factor agents (anti-VEGF), anti-VEGF/anti-angiopoietin-2 (Ang-2 agents), , device implant.
  • For Part 3: History of treatment with any of the following: Aflibercept 2 mg, ranibizumab, bevacizumab, or anti-VEGF biosimilars within 90 days prior to Day 1; Aflibercept 8 mg, brolucizumab, or faricimab within 120 days prior to Day 1; Triamcinolone acetonide (IVT, suprachoroidal, or periocular) within 120 days prior to Day 1; Dexamethasone intravitreal implant within 180 days prior to Day 1; Fluocinolone acetonide (FA) intravitreal implant within 3 years prior to Day 1; Device implant
  • History of uveitis, vitritis (grade trace or above), and/or scleritis in either eye
  • Active intraocular inflammation in either eye
  • Any previously documented or current proliferative diabetic retinopathy (PDR) in the study eye
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
93 participants (estimated)

Study arms

  • Experimental
    Part 1: Multiple Ascending Dose (MAD) Monotherapy

    Participants will receive multiple doses of RO7823653, administered as an IVT injection.

    Drug: RO7823653

  • Experimental
    Part 2: Optional Multiple-Dose Expansion

    Participants will receive multiple doses of RO7823653 administered as an IVT injection, at or below the maximum tolerated dose (MTD) or maximum tested dose (MTeD), as determined during the MAD stage.

    Drug: RO7823653

  • Experimental
    Part 3: MAD (RO7823653 + Faricimab)

    Participants will receive multiple doses of RO7823653 along with faricimab, administered as an IVT injection.

    Drug: RO7823653 · Drug: Faricimab

Interventions

  • DrugRO7823653

    Participants will receive RO7823653 as an IVT injection per the schedule described in the protocol.

  • Participants will receive faricimab as an IVT injection per the schedule described in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Ocular Adverse Events (AEs) and Systemic AEs

    Time frame: Up to approximately 20 Weeks

Secondary outcomes

  1. Serum Concentrations of RO7823653

    Time frame: Up to approximately 20 Weeks

  2. Aqueous Humor Concentrations of RO7823653

    Time frame: Up to approximately 20 Weeks

  3. Percentage of Participants With Anti-Drug Antibodies (ADAs) to RO7823653

    Time frame: Up to approximately 20 Weeks

  4. Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score

    Time frame: Up to approximately 20 Weeks

  5. Change From Baseline in Retinal Thickness

    Time frame: Up to approximately 20 Weeks

  6. Recommended Dose of RO7823653

    Time frame: Up to approximately 20 Weeks

07

Study locations

12 of 12 sites recruiting
  • Associated Retina Consultants - Peoria - DocTrials - PPDS
    Peoria, Arizona 85381-3690, United States
    Recruiting
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211-1838, United States
    Recruiting
  • Bay Area Retina Specialists Medical Group - Vestrum - PPDS
    Walnut Creek, California 94598-5915, United States
    Recruiting
  • Retina Vitreous Associates of Florida
    St. Petersburg, Florida 33711-1141, United States
    Recruiting
  • Wilmer Eye Institute
    Baltimore, Maryland 21287-0005, United States
    Recruiting
  • Erie Retina Research, LLC - 300 State St
    Erie, Pennsylvania 16507-1429, United States
    Recruiting
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107-5109, United States
    Recruiting
  • Charles Retina Institute
    Germantown, Tennessee 38138-2405, United States
    Recruiting
  • Retina Research Institute of Texas
    Abilene, Texas 79606-1224, United States
    Recruiting
  • Austin Clinical Research, LLC
    Austin, Texas 78750-2298, United States
    Recruiting
  • Retina Consultants of Texas Westover Hills Retina Center
    San Antonio, Texas 78251, United States
    Recruiting
  • Piedmont Eye Center
    Lynchburg, Virginia 24502-4271, United States
    Recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 30 months after the start.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Feb 23, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Nov 17, 2028
CompletionEst.
Nov 17, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07425522
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Apr 21, 2026
Primary completion
Nov 17, 2028 (estimated)
Completion
Nov 17, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

Reference Study ID Number GR46431 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion